Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719443 | 0.82 | FABP3 (0.41) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL30010765 | 0.82 | TRPV4 (0.38) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL216708 | 0.82 | TRPV4 (0.38) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL10980384 | 0.82 | L3MBTL1 (0.32) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL3925075 | 0.82 | CA1 (0.39) | L3MBTL1SLC9A1SLC9A2ALDH1A1 | |
| SCHEMBL10435622 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL9164110 | 0.80 | SLC9A1 (0.33) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL11578768 | 0.80 | FABP3 (0.40) | L3MBTL1SLC9A1SLC9A2HPGDFABP3 | |
| Hydrochloric Acid SCHEMBL1005423 | 0.80 | FABP3 (0.40) | L3MBTL1SLC9A1SLC9A2HPGDFABP3 | |
| SCHEMBL9425114 | 0.77 | SLC9A1 (0.31) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| WO-2004096285-A2 | ANTI-INFECTIVE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0488336-B1 | 2-Substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases | YAMASA SHOYU KK (JP) | 1995-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | L3MBTL1 2434/4885SLC9A1 4096/4885SLC9A2 4513/4885 |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | L3MBTL1 2153/4885SLC9A1 4012/4885SLC9A2 4381/4885 |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | L3MBTL1 2133/4885SLC9A1 4364/4885SLC9A2 4714/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | L3MBTL1 192/4885SLC9A1 4659/4885SLC9A2 4788/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | L3MBTL1 192/4885SLC9A1 4659/4885SLC9A2 4788/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | L3MBTL1 2435/4885SLC9A1 3231/4885SLC9A2 3894/4885 |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | L3MBTL1 2435/4885SLC9A1 3231/4885SLC9A2 3894/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | L3MBTL1 2435/4885SLC9A1 3231/4885SLC9A2 3894/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | L3MBTL1 2435/4885SLC9A1 3231/4885SLC9A2 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.